Drug Trial Radar · NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
780
Planned (sponsor's estimate)
Start
Apr 3, 2024
Primary completion
Feb 21, 2034
Study completion Oct 23, 2034
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).
Conditions
- Non Small Cell Lung Cancer
Interventions
Sacituzumab tirumotecanBiological
Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 24 weeks
PembrolizumabBiological
Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
CisplatinDrug
Cisplatin is administered as 75 mg/m\^2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
PemetrexedDrug
Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m\^2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
GemcitabineDrug
Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m\^2 or 1250 mg/m\^2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
CarboplatinDrug
Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
PaclitaxelDrug
Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m\^2 or 200 mg/m\^2 IV infusion q3w for up to 12 weeks as background treatment.
Rescue medicationDrug
Participants are permitted to take rescue medications to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. Rescue medications include antihistamine, H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent, and granulocyte colony-stimulating factor. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR)Time frame: Up to ~ 93 months
Locations
271 sites in 31 countries. Site status is shown where the registry gives one.
UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060)
Little Rock, Arkansas · Recruiting
Highlands Oncology Group-Research Department ( Site 0062)
Springdale, Arkansas · Recruiting
Beverly Hills Cancer Center ( Site 0070)
Beverly Hills, California · Recruiting
The Angeles Clinic and Research Institute ( Site 0040)
Los Angeles, California · Completed
The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate ( Site 0079)
Los Angeles, California · Completed
UCLA Clinical & Translational Research Center (CTRC) ( Site 0033)
Los Angeles, California · Recruiting
Hoag Memorial Hospital Presbyterian ( Site 0096)
Newport Beach, California · Recruiting
St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002)
Orange, California · Recruiting
San Francisco Oncology Associates ( Site 0066)
San Francisco, California · Recruiting
Stamford Hospital ( Site 0083)
Stamford, Connecticut · Recruiting
Mayo Clinic in Florida ( Site 0014)
Jacksonville, Florida · Recruiting
Mount Sinai Cancer Center ( Site 0038)
Miami Beach, Florida · Recruiting
Mid Florida Hematology and Oncology Center ( Site 0018)
Orange City, Florida · Recruiting
Phoebe Putney Memorial Hospital ( Site 4016)
Albany, Georgia · Recruiting
Piedmont Atlanta Hospital ( Site 4000)
Atlanta, Georgia · Recruiting
Emory University School of Medicine-Phase I ( Site 0056)
Atlanta, Georgia · Recruiting
Northside Hospital ( Site 0055)
Atlanta, Georgia · Recruiting
Centricity Research Columbus Cancer Center ( Site 0005)
Columbus, Georgia · Completed
Southeastern Regional Medical Center ( Site 0065)
Newnan, Georgia · Recruiting
Lewis Cancer and Research Pavilion ( Site 0063)
Savannah, Georgia · Recruiting
Archbold Cancer Center ( Site 0071)
Thomasville, Georgia · Recruiting
Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0017)
Elmhurst, Illinois · Completed
North Shore University Health System ( Site 4014)
Evanston, Illinois · Recruiting
Accellacare of Duly ( Site 4005)
Lisle, Illinois · Recruiting
Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0078)
Naperville, Illinois · Completed
Parkview Research Center at Parkview Regional Medical Center ( Site 0089)
Fort Wayne, Indiana · Recruiting
Indiana University Health Arnett Cancer Center ( Site 0076)
Lafayette, Indiana · Recruiting
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061)
Edgewood, Kentucky · Recruiting
LSU Health Baton Rouge North Clinic ( Site 4003)
Baton Rouge, Louisiana · Recruiting
Our Lady of the Lake Physician Group-Medical Oncology ( Site 0080)
Baton Rouge, Louisiana · Recruiting
New England Cancer Specialists ( Site 0095)
Westbrook, Maine · Recruiting
Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0027)
Minneapolis, Minnesota · Recruiting
Mayo Clinic - Rochester ( Site 0073)
Rochester, Minnesota · Recruiting
Mercy South - David M Sindelar Cancer Center ( Site 0098)
St Louis, Missouri · Recruiting
Mercy Research - David C. Pratt Cancer Center ( Site 0006)
St Louis, Missouri · Recruiting
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037)
Reno, Nevada · Recruiting
Atlantic Health Morristown Medical Center ( Site 0077)
Morristown, New Jersey · Recruiting
Cayuga Medical Center ( Site 0086)
Ithaca, New York · Recruiting
University Hospital at Stony Brook ( Site 0054)
Stony Brook, New York · Recruiting
White Plains Hospital ( Site 0091)
White Plains, New York · Recruiting
Showing 40 of 271 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.